Skip to main content
SpringerLink
Log in

Authors’ Reply to: Tomoyuki Kawada’s Comment on: “All-Cause and Drug-Related Medical Events Associated with Overuse of Gabapentin and/or Opioid Medications: A Retrospective Cohort Analysis of a Commercially Insured US Population’’

  • Letter to the Editor
  • Published:
Drug Safety Aims and scope Submit manuscript

The Original Article was published on 03 May 2018

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kawada T. Comment on: “All-cause and drug-related medical events associated with overuse of gabapentin and/or opioid medications: A retrospective cohort analysis of a commercially insured US population”. Drug Saf. 2018. https://doi.org/10.1007/s40264-018-0670-2.

    Article  PubMed  Google Scholar 

  2. Hah J, Mackey SC, Schmidt P, et al. Effect of perioperative gabapentin on postoperative pain resolution and opioid cessation in a mixed surgical cohort: a randomized clinical trial. JAMA Surg. 2017. https://doi.org/10.1001/jamasurg.2017.4915 (Epub ahead of print).

    Article  Google Scholar 

  3. Cavalcante AN, Sprung J, Schroeder DR, et al. Multimodal analgesic therapy with gabapentin and its association with postoperative respiratory depression. Anesth Analg. 2017;125(1):141–6. https://doi.org/10.1213/ANE.0000000000001719.

    Article  PubMed  CAS  Google Scholar 

  4. Savelloni J, Gunter H, Lee KC, et al. Risk of respiratory depression with opioids and concomitant gabapentinoids. J Pain Res. 2017;10:2635–41. https://doi.org/10.2147/jpr.s144963 (eCollection 2017).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Gomes T, Juurlink DN, Antoniou T, et al. Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case-control study. PLoS Med. 2017;14(10):96. https://doi.org/10.1371/journal.pmed.1002396 (eCollection 2017 Oct).

    Article  Google Scholar 

  6. Peckham AM, Evoy KE, Covvey JR, et al. Predictors of gabapentin overuse with or without concomitant opioids in a commercially insured US population. Pharmacotherapy. 2018;38(4):436–443. https://doi.org/10.1002/phar.2096 (Epub 2018 Mar 28).

    Article  PubMed  CAS  Google Scholar 

  7. World Health Organization. Information sheet on opioid overdose [Internet]. Nov 2014 [cited 2 April 2018]. http://www.who.int/substance_abuse/information-sheet/en/. Accessed 2 April 2018.

  8. Peckham AM, Fairman KA, Sclar DA. Policies to mitigate nonmedical use of prescription medications: How should emerging evidence of gabapentin misuse be addressed? Expert Opin Drug Saf. 2017. https://doi.org/10.1080/14740338.2017.1390081 (Epub ahead of print).

    Article  PubMed  Google Scholar 

  9. Peckham AM, Fairman KA, Sclar DA. Call for increased pharmacovigilance of gabapentin. BMJ. 2017;30(359):j5456. https://doi.org/10.1136/bmj.j5456.

    Article  Google Scholar 

  10. U.S. Food & Drug Administration. FDA requires strong warnings for opioid analgesics, prescription opioid cough products, and benzodiazepine labeling related to serious risks and death from combined use [Internet]. 31 Aug 2016 [cited 2 April 2018]. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm518697.htm. Accessed 2 April 2018.

  11. Bloomberg. America’s next big drug problem: Doctors and lawmakers need to take benzodiazepines seriously, before it’s too late [Internet]. 9 Mar 2018 [cited 2 April 2018]. https://www.bloomberg.com/view/articles/2018-03-09/america-s-next-big-drug-problem-benzodiazepines. Accessed 2 April 2018.

  12. Van Baelen L, De Ridder K, Antoine J, et al. Utilization of gabapentin by people in treatment for substance use disorders in Belgium (2011–2014): a cross-sectional study. Arch Public Health. 2018;76:17. https://doi.org/10.1186/s13690-018-0254-8 (eCollection 2018).

    Article  PubMed  PubMed Central  Google Scholar 

  13. Goodman CW, Brett AS. Gabapentin and pregabalin for pain—is increased prescribing a cause of concern? N Engl J Med. 2017;377(5):411–4. https://doi.org/10.1056/NEJMp1704633.

    Article  PubMed  Google Scholar 

  14. Starcevic V. Benzodiazepines for anxiety disorders: maximising the benefits and minimising the risks. Adv Psychiatr Treat. 2012;18(4):250–8. https://doi.org/10.1192/apt.bp.110.008631.

    Article  Google Scholar 

  15. Greenblatt HK, Greenblatt DJ. Gabapentin and pregabalin for the treatment of anxiety disorders. Clin Pharmacol Drug Dev. 2018;7(3):228–32. https://doi.org/10.1002/cpdd.446.

    Article  PubMed  CAS  Google Scholar 

  16. Mason BJ, Quello S, Shadan F. Gabapentin for the treatment of alcohol use disorder. Expert Opin Investig Drugs. 2018;27(1):113–24. https://doi.org/10.1080/13543784.2018.1417383 (Epub 2017 Dec 23).

    Article  PubMed  CAS  Google Scholar 

  17. Mack A. Examination of the evidence for off-label use of gabapentin. J Manag Care Pharm. 2003;9(6):559–68. https://doi.org/10.18553/jmcp.2003.9.6.559.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy Practice, College of Pharmacy-Glendale, Midwestern University, 19555 N. 59th Avenue, Glendale, AZ, USA

    Alyssa M. Peckham, Kathleen A. Fairman & David A. Sclar

Authors
  1. Alyssa M. Peckham
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kathleen A. Fairman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David A. Sclar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alyssa M. Peckham.

Ethics declarations

Funding

No sources of funding were used to assist in the preparation of this letter.

Conflict of interest

Alyssa M. Peckham, Kathleen A. Fairman, and David A. Sclar declare have no conflicts of interest that are directly relevant to the content of this letter.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Peckham, A.M., Fairman, K.A. & Sclar, D.A. Authors’ Reply to: Tomoyuki Kawada’s Comment on: “All-Cause and Drug-Related Medical Events Associated with Overuse of Gabapentin and/or Opioid Medications: A Retrospective Cohort Analysis of a Commercially Insured US Population’’. Drug Saf 41, 643–644 (2018). https://doi.org/10.1007/s40264-018-0671-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40264-018-0671-1

Search

Navigation